SEC Form 4 · accession 0001562180-17-003064
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kyle Lefkoff
Director
Period of report
Sep 29, 2017
Accepted (ET)
Sep 29, 2017 · 6:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 29, 2017 | M | 45,000 | $10.58 | A | 51,585 | D | |
| Common Stock | Sep 29, 2017 | S | 38,865 | $12.31 | D | 12,720 | D | |
| Common StockF2 | holding | — | — | — | 45,000 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F3 | $10.58 | Sep 29, 2017 | M | 45,000 | D | Nov 1, 2010 | Nov 1, 2017 | Common Stock | 45,000 | 0 | D |
Explanation of responses
- F1This Form 4 is reporting the exercise by the reporting person of an option scheduled to expire on November 1, 2017 and the sale of a portion of the option shares to satisfy payment of the option exercise price.
- F2Comprised of 30,000 shares of common stock in trust for the benefit of Mr. Lefkoff's minor children and 15,000 shares of common stock held by BV Partners III Profit Sharing account for the benefit of Mr. Lefkoff.
- F3The option vested in 3 equal annual installments beginning on November 1, 2008.